ISCG vs. RZG: Which Small-Cap Growth ETF Is the Better Buy for Investors?

ISCG (iShares Morningstar Small-Cap Growth ETF) charges a much lower 0.06% expense ratio versus RZG’s 0.35% (about $6 vs. $35 per $10,000 invested), while offering broader diversification (933 holdings vs. 125). Over the past year, RZG has outperformed with total returns of 38.84% vs. ISCG’s 27.53%, while ISCG shows lower 5-year max drawdown (41.47% vs. 38.33%). The key tradeoff is cheaper, diversified exposure (ISCG) versus a more concentrated momentum/growth tilt that recently delivered stronger returns (RZG).

Analysis

This is mostly an implementation decision, not a high-conviction market event. In small-cap growth, returns are usually driven by a narrow set of names, so RZG is effectively a momentum tilt wrapped in an ETF, while ISCG is the cheaper way to own the same factor with less single-name blowup risk. The fee gap only compounds over multi-year horizons; over the next 1-3 months, relative performance will be driven far more by rates, breadth, and whether the current leadership cohort keeps delivering upside revisions.

The second-order issue is concentration around industrial and tech small caps that are still highly sensitive to capex and financing conditions. If that narrow leadership persists, RZG can keep outperforming despite higher costs; if earnings revisions broaden or risk appetite rotates toward lower-quality small caps, ISCG should hold up better because it is less exposed to one or two top holdings derailing the sleeve. The real winners are the names with durable operating leverage and balance-sheet discipline; the losers are weaker growers that never become meaningful index drivers and get washed out by a broader basket.

Contrarian read: the market tends to over-obsess about expense ratio and underweight implementation costs, turnover, and factor timing. In a volatile small-cap regime, the real decision is whether you want persistent beta or a tactical momentum sleeve. If small-cap growth breadth fades or credit conditions tighten, the concentration premium in RZG can reverse quickly; if that happens, the thesis is falsified by relative underperformance versus ISCG over the next few rebalance cycles.

Key Decisions for Investors

• For any new core small-cap growth allocation, prefer ISCG and buy on broad small-cap weakness over the next 2-6 weeks. Risk/reward: lower fee and broader diversification should win over 6-18 months unless the tape stays narrowly momentum-led.